|

SHR-1316 Clinical Trials

6 actively recruiting trials

Also known as: HTI-1088

Pipeline

Phase 2: 5Phase 1/2: 1

Top Sponsors

  • Fudan University4
  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.2

Indications

  • Cancer6
  • Breast Cancer4
  • HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer1
  • Hormone Receptor Negative Tumor1
  • Hormone Receptor Positive Tumor1

Other6 trials

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Phase 2
A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
Phase 2
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Phase 1/2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
Phase 2
Reverse Triple Negative Immune Resistant Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.